Ligand Pharmaceuticals | LGND - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Agenus USD 35M 32M 2026-03
Amgen USD 12.04B 2.91B 2026-03
Anika Therapeutics USD 41.02M 16.46M 2026-03
Arrowhead Research USD 201.64M 112.94M 2025-12
Baxter International USD 2.02B 51M 2026-03
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Eli Lilly USD 5.28B 1.99B 2026-03
Enanta Pharmaceuticals USD 37.44M 5.14M 2025-12
Enviri Corporation USD 105.7M 2.03M 2026-03
Gilead Sciences USD 7.56B 234M 2025-12
GlaxoSmithKline GBP 3.44B 292M 2026-03
Glaxosmithkline GBP 3.3B 303M 2025-09
Heron Therapeutics USD 26.12M 2.53M 2026-03
Insmed USD 582.19M 71.74M 2026-03
Intrexon USD 9.34M 1.77M 2024-06
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
Karyopharm Therapeutics USD 60.54M 22.87M 2025-12
Ligand Pharmaceuticals USD 115.08M 59.85M 2026-03
MacroGenics USD 66.52M 9.3M 2026-03
Merck USD 5.33B 9.24B 2026-03
Pacira USD 144.31M 14.24M 2026-03
Pfizer USD 1.7B 561M 2026-03
Rigel Pharmaceuticals USD 48.53M 4.87M 2025-09
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Veracyte USD 263.14M 99.44M 2026-03